CITIUS ONCOLOGY, INC.
CTOR · XNASCIK 1851484fmd_1DJNB8MWYVH836QWR213HVFACEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2020 to Jun 30, 2026, 20 periods
| Line item | FY2023 | FY2023 | FY2024 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Research and development | – | 4 | – | 5 | 6 |
| Total operating expenses | – | 12 | – | 21 | 24 |
| Operating income | (0) | – | – | (21) | (24) |
| Interest expense | – | – | – | – | 0 |
| Interest and investment income | – | – | – | – | 0 |
| Other non-operating income (expense) | 1 | – | 3 | – | (0) |
| Income before taxes | – | (12) | – | (21) | (24) |
| Income tax expense | – | 1 | – | 1 | 1 |
| Net income from continuing operations | – | (13) | – | (21) | (25) |
| Net income | 0 | – | – | (21) | (25) |